AOD-9604 10mg

Core Mechanisms Targeted Lipolysis:

It stimulates the breakdown of stored fat (lipolysis) and inhibits the formation of new fat cells (lipogenesis).

Selective Action:

Unlike full hGH, AOD-9604 does not significantly increase IGF-1 levels or affect blood sugar and insulin resistance.

Beta-3 Receptor Interaction:

It is believed to work partly by increasing the expression of -adrenergic receptors, which are critical for fat metabolism in adipocytes.

Potential Benefits in Research:

Weight Management:

While often marketed for rapid fat loss, clinical evidence in humans shows modest results, primarily effective when combined with a calorie-controlled diet and exercise.

Joint and Bone Health:

Preliminary studies suggest it may boost proteoglycan and collagen production, potentially aiding in cartilage repair and bone regeneration.

Reduced Systemic Risk:

Because it doesn't stimulate general tissue growth, it avoids common hGH risks like joint pain or abnormal tissue growth.

Safety and Side Effects:

AOD-9604 is generally well-tolerated. Reported side effects are typically mild and include: Injection site reactions Redness, swelling, or itching.

General discomfort:

Mild nausea, headaches, or upset stomach.

Legal and Regulatory Status FDA Status:

AOD-9604 is not FDA-approved for the treatment of obesity or any other medical condition. FDA Category 2 Bulks List - In late 2023, the FDA added AOD-9604 to the Category 2 Bulks List, effectively restricting it from being used by compounding pharmacies due to concerns about safety data and immunogenicity.

WADA Banned:

It is strictly prohibited in competitive sports at all times under the WADA Prohibited List.

Research Use:

It is currently primarily available as a "research chemical" not intended for human consumption.